The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans

Kevin S. Thorneloe, Armin Sepp, Sean Zhang, Laura Galinanes-Garcia, Paul Galette, Wasfi Al-Azzam, Danielle J. Vugts, Guus van Dongen, Phillip Elsinga, Johan Wiegers, Andor W. J. M. Glaudemans, Veena Vincent, Jessica Renaux, Matt Szapacs, Mary Birchler, Matthew Cleveland, Mats Bergstrom and Marie Davies

Abstract
Conjugation or fusion to AlbudAbs™ (albumin-binding domain antibodies) is a novel approach to extend the half-life and alter the tissue distribution of biological and small molecule therapeutics. To understand extravasation kinetics and extravascular organ concentrations of AlbudAbs in humans, we studied tissue distribution and elimination of a non-conjugated 89Zr-labeled AlbudAb in healthy volunteers using positron emission tomography/computed tomography (PET/CT).

Methods: A non-conjugated AlbudAb (GSK3128349) was radiolabeled with 89Zr and a single 1 mg (~ 15 MBq) dose intravenously administered to eight healthy males. 89Zr-AlbudAb tissue distribution was followed for up to 7 days with four whole-body PET/CT scans. 89Zr-AlbudAb tissue concentrations were quantified in organs of therapeutic significance, measuring standardized uptake value and tissue/plasma ratios. Plasma pharmacokinetics were assessed by gamma counting and LC-MS/MS of blood samples.

Results: 89Zr-AlbudAb administration and PET/CT procedures were well tolerated, with no drug-related immunogenicity or adverse events. 89Zr-AlbudAb rapidly distributed throughout the vasculature, with tissue/plasma ratios in the liver, lungs, and heart relatively stable over 7 days post-dose, ranging between 0.1 and 0.5. The brain tissue/plasma ratio of 0.025 suggested minimal AlbudAb blood-brain barrier penetration. Slowly increasing ratios in muscle, testis, pancreas, and spleen reflected either slow AlbudAb penetration and/or 89Zr residualization in these organs. Across all tissues evaluated, the kidney tissue/plasma ratio was highest (0.5–1.5 range) with highest concentration in the renal cortex. The terminal half-life of the 89Zr-AlbudAb was 18 days.

Conclusion: Evaluating the biodistribution of 89Zr-AlbudAb in healthy volunteers using a low radioactivity dose was successful (total subject exposure ~ 10 mSv). Results indicated rapid formation of reversible, but stable, complexes between AlbudAb and albumin upon dosing. 89Zr-AlbudAb demonstrated albumin-like pharmacokinetics, including limited renal elimination. This novel organ-specific distribution data for AlbudAbs in humans will facilitate a better selection of drug targets to prosecute using the AlbudAb platform and significantly contribute to modeling work optimizing dosing of therapeutic AlbudAbs in the clinic.

Keywords: Domain antibody, Albumin, AlbudAb, PET/CT, Biodistribution, 89Zr
Introduction

Fully human heavy and light chain variable domain antibodies (dAbs) display good biochemical, biophysical, and antigen-binding affinities [1–3], but their low molecular weight (10–15 kDa) renders them susceptible to rapid renal clearance that limits their therapeutic potential. While this aspect has been overcome with albumin-binding dAbs, as exemplified by Exendin-4 AlbudAb demonstrating a reduction in glucose and insulin in humans, very little is known about the tissue penetration properties of AlbudAbs™ in humans. This information is critical to modeling tissue concentrations, target engagement, and thereby making predication for clinical efficacy.

GSK3128349, a member of the AlbudAb platform, is a light chain dAb with high affinity for human albumin (Kd = 0.85 nM) and can be conjugated or fused to a therapeutic biologic or small molecule to extend their plasma half-lives. Albumin is found at high concentrations in plasma, but also in extravascular spaces [4, 5], and therefore AlbudAb tissue distribution is likely to extend beyond the blood. In combination with plasma concentration measurements, positron emission tomography/computed tomography (PET/CT) [6–8] provides the capability to explore not only the steady-state, but importantly also the kinetics of AlbudAb extravasation. Understanding the kinetics provides the opportunity to assess the turnover of AlbudAb in extravascular organ compartments, and estimate the level of target engagement with respect to dose and time [9].

Positron emission tomography (PET) imaging of proteins requires measurement of a slower tissue penetration rate and longer plasma exposure than typical for small molecule drugs. Proteins do not diffuse across plasma membranes and extravasation predominantly takes place via paracellular pores. Zirconium-89 ($^{89}$Zr), with a half-life of 3.3 days, is therefore a radiolabel of choice for protein PET studies, remaining detectable for up to 10 days even at the low dose levels which are deemed appropriate in clinical studies [10, 11]. Protein labelling methods for $^{89}$Zr utilize conjugation of desferrioxamine derivates and form very stable Zr complexes [10, 12, 13].

In the present study, we administered $^{89}$Zr-GSK3128349 AlbudAb to eight healthy male volunteers and used a combination of PET/CT, scintillation counting, and mass spectrometry in an adaptive design to follow the time course of AlbudAb tissue and plasma concentrations simultaneously. These results will facilitate quantitative insight into target accessibility for AlbudAbs across various human organs and improve the likelihood of success in developing AlbudAb-based therapeutics.

Materials and methods

Subjects

Eight healthy male participants between 50 and 65 years of age were enrolled. The higher age range was motivated to limit lifetime cancer risk from radiation exposure, as outlined by the International Commission on Radiological Protection [11]. The body mass index (BMI) for the participants ranged between 19.0 and 31.0 kg/m$^2$, with full details given in the Additional file 1. The study was approved by the appropriate regulatory and ethics committees (UMCG Medisch Ethische Commissie, Groningen, Netherlands) as required, and conducted in accordance with the International Conference on Harmonization for Good Clinical Practice and the principles of the Declaration of Helsinki. It was monitored by an Internal Safety Review Committee. Informed consent was obtained from all individual participants included in the study. The study was listed on ClinicalTrials.gov (NCT02829307).

AlbudAb production and radiolabeling

GSK3128349 was manufactured and tested to ensure quality, identity, potency, and safety in accordance with current GSK Good Manufacturing Practices (cGMP). $^{89}$Zr was coupled to unlabeled GSK3128349 via the bifunctional chelate desferal at the VU University Medical Center [13]. See Additional file 1. Procedures for radiolabelling of GSK3128349 with $^{89}$Zr were validated with respect to stepwise quality controls and assessment of final product quality. A single batch of GSK3128349 was used for production of all $^{89}$Zr-GSK3128349 radiolabeled batches.

$^{89}$Zr-GSK3128349 was diluted with unlabeled GSK3128349 to achieve a specific activity of 15 MBq/mg, with the $^{89}$Zr-GSK3128349 constituting around 0.015% of the total 1 mg GSK3128349 protein administered. A 1 mg total dose was utilized, as based on the pharmacokinetic properties of GSK3128349 it was deemed the minimum dose required to enable measurement of GSK3128349 plasma concentrations by mass spectrometry.

Study design

Participants were screened up to 28 days before entering the clinic, when on day 1 a single intravenous (IV) dose of 1 mg of 15 MBq/mg $^{89}$Zr-GSK3128349 was administered (Additional file 1: Figure S1). Participants were discharged from the clinic on day 2, and overall underwent four PET/CT scans within the 7-day post-dose period. Multiple blood samples were taken for up to 42 days post-dosing to analyze plasma radioactivity, GSK3128349 concentration, and presence of anti-GSK3128349 antibodies.
Using data from the first two individuals, the organ and whole-body radiation exposure was calculated using OLINDA software to confirm that the effective doses were below 10 mSv (as outlined by the International Commission on Radiological Protection) [11]. As a result, no reduction in administered radioactivity was deemed necessary for the remaining six participants. Anonymised individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.

**PET procedures and analysis**

The exact amount of administered radioactivity was determined by measurements of the injection syringe before and after administration. The IV infusion of 10 mL was administered over approximately 20 min. All scanning and blood sampling times refer to start of the infusion.

The PET scanning performed from head to mid-thigh was done using two EARL accredited Biograph mCT 64 slice PET/CT systems from Siemens, Knoxville, USA. The scanning time per bed position was typically 5 min but increased to 9 min in the later scans to enhance detection. Images were reconstructed with full corrections for attenuation and scatter, including a post-processing filter of 6.5 mm giving a resolution of 7 mm. The reconstructions were done including PSF (point-spread function) and TOF (time-of-flight) and conform to the current EARL specifications. The low-dose CT was performed at each PET scanning session for attenuation correction with settings to allow for no more than 0.5 mSv per session.

In the PET images, volumes of interest (VoI) were outlined in the major organs, using an ellipsoid fitting inside the organ, avoiding border effects. The average radioactivity concentration was determined and represented as SUVmean (SUV corrected for injected radioactivity and body weight). For smaller organs or structures, the principle of SUVpeak was applied, averaging over a sphere of 1 cm³. For some organs with uncertain visibility in the PET images, the delineation was aided by the CT scan. All SUV values were decay corrected to the start time of tracer administration.

The lowest theoretical value for the tissue-plasma ratio \( \left( \frac{t}{p} \right)_{\min} \) is calculated from Eq. 1,

\[
\left( \frac{t}{p} \right)_{\min} = \frac{V_{p,org}}{V_{org}}
\]

(1)

where \( V_{p,org} \) is the organ plasma volume and \( V_{org} \) the total volume. The highest theoretical value for the tissue-plasma ratio \( \left( \frac{t}{p} \right)_{\max} \) corresponds to the situation where the interstitial concentration is equal to that in plasma and calculated from Eq. 2,

\[
\left( \frac{t}{p} \right)_{\max} = \frac{V_{p,org} + V_{I,org}}{V_{org}}
\]

(2)

where \( V_{I,org} \) is the organ interstitial volume. All respective volume values were taken from the parameter set compiled by Shah and Betts [14].

**Pharmacokinetics**

Plasma samples were collected for the first two subjects and encompassed pre-dose, 1, 3, 6, 8 h and 1, 2, 3, 5, and 12 days after administration, respectively, and analyzed using gamma counting and liquid chromatography tandem mass spectrometry (LC-MS/MS) for quantitation of GSK3128349. Additional samples were taken at 19, 30, and 43 days, but only analyzed with respect to total GSK3128349 using LC-MS/MS. The timing of the blood sampling for the remaining subjects was modified as determined most appropriate from observation of data from the first two subjects. Blood samples were always taken in conjunction with PET scanning. \(^{89}\)Zr-GSK3128349 plasma radioactivity was measured in a well counter cross-calibrated with the camera and decay corrected to the start of administration. Plasma concentrations of total GSK3128349 were determined by trypsin digestion and solid-phase extraction of the specific LLILAFSR peptide fragment derived from the AlbudAb complementarity determining region, which was quantified by LC-MS/MS analysis [15].

Cumulative urine was collected for the first 24 h after dosing to determine the percent of administered radioactivity recovered in urine. If the total amount of radioactivity excreted in urine exceeded 3% for the first two subjects, then further discrete urine samples would be taken for subsequent subjects.

Non-compartmental analysis (NCA) of the plasma pharmacokinetics of both \(^{89}\)Zr-labeled as well as unlabeled GSK3128349 AlbudAb was performed using Matlab 2017b SimBiology v5.7.

**Safety and immunogenicity**

Physical examinations, medical history, ECG, and clinical laboratory measurements were performed before and after dosing GSK3128349 on day 1 and on day 2. Routine hematology, serum chemistry, and urine analysis were performed on day −1, 2, 6, 13 (± 1), 20 (± 2), and 21 (± 2). The presence of antibodies to GSK3128349 was assessed using an analytically validated bridging electrochemiluminescent (ECL) immunoassay. Briefly, serum samples collected on day 1 (before dosing) or day 43 (± 2; post dosing) were incubated for 1 h with biotinylated GSK3128349 and sulfo-TAG-labeled GSK3128349 before addition to a streptavidin-coated MSD plate. After 1 h, the plate was washed (PBS-tween) and read on a MSD Sector Imager Reader 600. Normal human serum and
serum spiked with an anti-IgG (Vk) mAb were included as negative and positive controls, respectively.

Results
Subjects and safety
Eight subjects were enrolled into the study (Table 1), with inclusion/exclusion criteria listed in the Additional file 1. The mean administered radioactivity was 14.0 ± 0.9 MBq (range, 12.77–15.03 MBq). The effective dose from administered radioactivity for the first two subjects were 5.4 and 7.5 mSv, which together with four low dose CT scans (0.5 mSv/scan) gave total effective radiation doses of 7.4 and 9.5 mSv. The average radiation exposure across all study subjects was 0.448 mSv/MBq, with a mean subject exposure of 8.3 mSv.

89Zr-GSK3128349 was well tolerated and no adverse events related to the AlbudAb were observed in any of the subjects. No observed changes in vital signs, laboratory results, or electrocardiograms were deemed clinically significant. One subject was found to have pre-existing anti-GSK3128349 antibodies at the start of study. In this subject, the titres were low and similar at follow-up, suggesting that these anti-GSK3128349 antibodies were not related to dosing. None of the subjects developed anti-GSK3128349 responses during the study.

PET/CT images
As expected, the PET/CT images demonstrated an initial dominant vascular distribution, highlighted by signals in cardiac blood pools and large vessels. This was particularly pronounced in images acquired shortly after dosing (Fig. 1). A gradual increased contrast between the kidneys and the rest of the body developed over time. Transaxial images demonstrated a punctate signal, which may reflect noise arising from the low dose of label or local vasculature, as in the study 89Zr-GSK3128349 concentration in the blood always exceeded the tissue concentrations, except for prominent uptake in the renal cortex. Features of major organs were still identifiable, as shown for the heart, kidneys, liver, and spleen (Fig. 2).

Particularly, the heart chambers and aorta were clearly visible.

Standardized uptake values
The mean standard uptake values (SUV) measured by PET/CT characterize the concentration of 89Zr-GSK3128349 in the region of interest (ROI) relative to the body average. The mean SUVs ranged from very low values in brain and muscle to high values in blood pools and renal cortex (Fig. 3). In most organs, except muscle and renal cortex, there was a decrease with time. Organ time-activity data across all subjects suggest that tissue distribution steady state is achieved within approximately 100 h after dosing.

Plasma pharmacokinetics
The maximal plasma concentration of GSK3128349 occurred in the first sample drawn at 60 min (390 ± 60 ng/mL), suggesting an initial volume of distribution around 2.5 L, close to that of the plasma volume in humans. The plasma pharmacokinetics of 89Zr-GSK3128349 measured by scintillation, and of total GSK3128349 measured by mass spectrometry, followed a bi-exponential time course (Fig. 4, radio pharmacokinetics (PK) decay-corrected for the 89Zr). We found the variation between subjects was small, with only one outlier (at 288 h) excluded from the analysis as it deviated from the mean by 8.4 standard deviations. The initial distribution (alpha) phase, during which the plasma concentration reduced relatively rapidly, lasted for approximately 100 h, and reflects extravasation of the dosed protein into organ interstitial spaces. The beta phase with slower decline was described by first-order kinetics, and characterized as the plasma elimination half-life.

The pharmacokinetic parameters, established through non-compartmental analysis, are presented in Table 2 (and Additional file 1: Table S2). The mean volume of distribution at steady state (Vss) and clearance were 5.4 ± 1.2 L and 9.7 ± 1.6 mL/h, respectively. The terminal half-life of the GSK3128349 AlbudAb was estimated as

| Subject | Age (years) | Weight (kg) | BMI (kg/m²) | Dose of radioactivity (MBq) |
|---------|-------------|-------------|-------------|---------------------------|
| 105     | 54          | 76.1        | 25.7        | 12.77                     |
| 110     | 53          | 72.2        | 22.8        | 14.53                     |
| 122     | 54          | 68.6        | 23.5        | 14.24                     |
| 123     | 60          | 92.3        | 27.6        | 13.27                     |
| 125     | 53          | 91.8        | 27.4        | 14.64                     |
| 127     | 56          | 70.2        | 21.4        | 14.72                     |
| 132     | 54          | 73.0        | 20.9        | 15.03                     |
| 135     | 56          | 83.1        | 23.3        | 13.06                     |

Table 1 Eight Caucasian male subjects were enrolled into the study. All subjects had four PET/CT scans, except subject 122 who declined further participation after the first two scanning sessions for availability reasons.
422 ± 40 h (17.5 ± 1.7 days); strikingly similar to human albumin [16].

**Urine excretion of radioactivity**
The cumulative urine radioactivity obtained during the 24 h after 89Zr-GSK3128349 infusion contained a total of 3.8 and 4.0% of administered radioactivity in the first two subjects. Since 3% in the first two subjects was dictated per protocol as the threshold to initiate further urine sampling, further urine collection (single void samples) was performed in all subsequent subjects. 89Zr-GSK3128349 urinary concentration in samples collected beyond 24-h post-dose was about one-third of that in the first 24 h sample (average concentration on day 1 was 495 ± 268 Bq/mL and 178 ± 142 Bq/mL on day 6).

**Tissue-to-plasma ratios**
The tissue-to-plasma (t/p) radioactivity concentration ratios for each organ (Fig. 5) predominantly characterize the process of 89Zr-GSK3128349 AlbudAb extravasation into interstitial organ spaces. The ratio can change in time, reflective of the rate of the process. We plotted the measured t/p levels from the current study along with the minimal (if the label was confined to the vasculature only) and maximal (if label concentration in organ interstitial space was equal to that in plasma) expected ratios, based on work by Shaw and Betts [14].

We found that in the case of lungs, liver, and spleen, the highest expected t/p ratio was reached quickly, and remained high for the duration of the study, suggesting a rapid distribution of AlbudAb into interstitial spaces in lung, liver, and spleen. In contrast, in brain, the tissue-plasma ratio remained at the theoretical minimum level throughout the study, suggesting that the AlbudAb remained predominantly confined to the brain vasculature.

For numerous organs, the tissue-plasma ratios increased with time, reflecting time-dependent extravasation. Organs in this group were thigh muscle, parotid gland, pancreas, and bone marrow.

Finally, in a few cases, the observed t/p ratio exceeded the theoretical maximum. In heart measurements, the observed value of around 0.5 was significantly higher than the maximal predicted value, being instead closer to that expected for blood. This is expected given that the ROI encapsulated the entire organ including blood present in the heart chambers. In the case of kidneys, the initial value is close to the expected maximum but continues to increase, demonstrating predominance in the cortex. Finally, we also observed significant radiolabel accumulation beyond the theoretical maximum in testis.

**Discussion**
The small size of antibody fragments delivers the benefit of improved tissue penetration [17, 18], but also renders them sensitive to rapid renal elimination [19]. Members of the AlbudAb platform, such as GSK3128349, have been engineered to bind albumin with high affinity in
several species including humans, and can be genetically fused or chemically conjugated to therapeutic agents (examples include a domain antibody against tumor necrosis factor receptor 1 [20] and apelin [21] as well as the exendin-4 AlbudAb which demonstrated an ability to reduce glucose and insulin in humans [22]). Given that many therapeutic targets are expressed as cell membrane receptors on tissue-embedded cells not exposed directly to plasma, and that GSK3128349 binds albumin also present in the interstitial fluid and lymph, AlbudAbs likely extravasate into organs of the body. To this end, the current PET/CT study of $^{89}$Zr-GSK3128349 in humans has provided a unique insight into the distribution properties of the AlbudAb platform into various organs. Due to the size of the AlbudAb-albumin complex, the extravasation is likely to be dominated by filtration, like in the case of antibodies [23]. The rate of the process varies from rapid in organs with leaky vasculature (liver, spleen) to slow or imperceptible in the brain. It is likely that the properties of the AlbudAb and albumin will outweigh those of any future potential therapeutic payload, i.e., the drug will remain extracellular and will not diffuse across the plasma membrane. The PK of an AlbudAb conjugated with a therapeutic may well be affected by target-mediated disposition if membrane proteins are targeted by the therapeutic agent. More quantitative descriptions of tissue penetration and target engagement will be possible for specific
Fig. 3 The SUV time course data for $^{89}$Zr-GSK3128349 tissue distribution. Individual subjects are identified by the color. While some organs could be measured as whole organs (e.g., kidneys, liver, and spleen), some could only be sampled in part (e.g., muscle and lungs). Subject 105-light blue, 110-orange, 122-gray, 123-yellow, 125-purple, 127-green, 132-dark blue, 135-brown.
therapeutic AlbudAbs within the framework of physiologically based pharmacokinetics [14, 19, 23].

This study included four adaptively modified PET/CT scan time-points per subject that yielded tissue penetration and elimination PK using only eight subjects. Plasma concentration time course data obtained via LC-MS/MS compared to radiolabel PK yielded very similar results, suggesting that the presence of the radiolabel (on only ~0.015% of the molecules dosed) does not affect the tissue distribution properties of GSK3128349. The initial volume of distribution (calculated from the plasma Cmax) was very close to human plasma volume, indicating that the IV dose is rapidly diluted in the circulation after dosing. A process significantly faster than the subsequent tissue distribution phase reaching steady-state in about 100 h, similar to that reported for albumin [16] and other large proteins such as intact monoclonal antibodies [24]. The 5.5 L steady-state volume of distribution for GSK3128349 is also typical for monoclonal antibodies whose distribution is unaffected by target-binding [25, 26]. Finally, the terminal half-life of GSK3128349 of 17.5 days is close to the 18–19 days reported for human albumin [27], implying that AlbudAb remains bound to albumin during endosomal recycling [28] and hence probably shares the albumin elimination pathway. Overall, the AlbudAb plasma kinetics properties described here are very similar to that of albumin, suggesting that the current AlbudAb PET study data may provide an indirect assessment of albumin distribution.

T/p ratios for several organs are significantly higher than expected from their respective organ vascular spaces alone but are instead more consistent with a summed combination of vascular and interstitial spaces. Although t/p ratios did not always reach a level to suggest a similar concentration in the vascular and interstitial compartments, this observation is consistent with Wiig et al. and Gyenge et al. [29–31] who have shown that there is an "exclusion space" in tissue on the order of 16–26% for albumin and antibodies, whereby a portion of the interstitial space is not accessible. "Exclusion space" estimates have only been made for a few organs, therefore our comparisons have used the estimated maximum t/p ratios (Fig. 5) based on an assumption that GSK3128349 can distribute into the full interstitial space with a concentration equal to that in plasma. However, filtration at the vascular barrier is expected to reduce the interstitial concentrations of plasma proteins in organs with continuous and fenestrated capillaries [32]. In addition, there can be a reduction in interstitial tissue volume for larger proteins, and therefore, the actual highest attainable t/p ratios could be lower than that presented herein. Consistent with this, the steady-state

Table 2 Plasma pharmacokinetic parameters for total GSK3128349

|        | AUC (0-inf) (ng/mL)*h | CL (mL/h) | MRT (h) | T½ (h) | V_ss (mL) |
|--------|-----------------------|-----------|---------|--------|-----------|
| Min    | 81,900                | 7.8       | 483     | 360    | 4344      |
| Max    | 128,598               | 12.2      | 657     | 477    | 6060      |
| Median | 97,904                | 10.2      | 562     | 428    | 5862      |
| Mean   | 105,482               | 9.7       | 565     | 422    | 5434      |
| STDEV  | 17,508                | 1.6       | 55      | 38     | 696       |

Fig. 4 Plasma PK of [89Zr]-GSK3128349 as detected by radio PK (red circles), and total GSK3128349 as detected by LC/MS (blue circles). Each dot represents data for a single time-point from a single subject.
volume of distribution measured in this study for GSK3128349 is twofold higher than the plasma volume, whereas the entire extravascular volume exceeds that of plasma by about fourfold, suggesting that GSK3128349 achieves around a two- to fourfold dilution during the extravasation process.

The data reported here suggest that GSK3128349 has a rapid access to the tissue interstitium in some organs (e.g., lung and liver due to fenestrated endothelium) and is virtually excluded from others (e.g., brain by the properties of the blood-brain barrier). The t/p ratio time course for 89Zr-GSK3128349 increases with time in several organs—especially noticeable in muscle, renal cortex, bone marrow, parotid gland, testis, and spleen which is likely to reflect the penetration of GSK3128349 into the interstitial space in these organs. The data are not sufficient to elucidate the exact mechanism for transfer from plasma to interstitium, but GSK3128349 bound to albumin can be expected to be transported across the capillary endothelium by filtration and diffusion, as described within the framework of two-pore hypotheses of extravasation [32].

PET measures the total tissue concentration of 89Zr, comprised of both the intact 89Zr-GSK3128349 protein in both vascular and interstitial spaces, as well as any potential 89Zr-containing degradation products due to the residualizing nature of the label. This is likely to be especially relevant in the case of kidneys, where the cellular uptake and catabolism of 89Zr-GSK3128349, as well as specific uptake and intracellularly retention of any residual free 89Zr, can lead to accumulation of the label [33, 34] and contribute to the overall signal.

We observed high PET signal in kidneys with an average final SUV of approximately 9, and even higher levels in the cortical region. The kidneys constitute less than 1% of body weight, indicating that the fraction of administered radioactivity captured by the kidneys is about 9%. At the same time, we found 3–4% of the administered radioactivity in the initial 24-h urine, which is the typical daily range for albumin passing through the glomerular barrier in humans [35]. Most protein found in urine is thought to be endocytosed via megalin-cubilin-mediated uptake in the proximal tubules of the renal cortex and to be degraded [35]. Our imaging data, which indicate significant accumulation of 89Zr in the renal cortex are in agreement with this given the residualizing nature of
The free fraction of GSK3128349 AlbudAb is expected to be in the region of \( \approx 0.002\% \) in plasma and in these conditions GSK3128349 acquires albumin-like properties in circulation and in organ extravascular compartments. These data contrast with shorter residence times observed for other similarly sized dAbs and smaller proteins that do not bind albumin and can be eliminated within hours by renal filtration.

The study also demonstrated significant differences between organs in respect of the kinetics of GSK3128349 AlbudAb extravasation, indicating that steady-state exposure in different organs may be different from that achievable with single doses. The results suggest rapid access to tissue interstitium in the liver, lungs, spleen, bone marrow, and other organs, with no extravasation and accumulation in the brain. Hence, the albumin-binding and distribution properties suggest that GSK3128349 has the potential to be a useful platform to carry therapeutic payloads to access tissues (with exception of CNS) with desirable pharmacokinetics.

**Additional file**

**Additional file 1: Materials.** AlbudAb production and radiolabeling. Materials. Quantification of plasma GSK3128349 by LC-MS/MS. Methods. PET image analysis. Methods. Subject cohort inclusion and exclusion criteria. Figure S1. Study outline and procedure. Table S1. Subject details. Table S2. Pharmacokinetic parameters. Figure S2. Maximum intensity projection, subject 127. Figure S3. PET/CT images, subject 127. Figure S4. Maximum intensity projection, subject 105. Figure S5. PET/CT images, subject 105. (DOCX 3305 kb)

**Abbreviations**

\(^{89}\text{Zr} \): Zirconium-89; AlbudAb: Albumin-binding domain antibodies; BMI: Body mass index; cGMP: Current Good Manufacturing Practices; dAb: Domain antibodies; ECL: Electrochemiluminescent; IV: Intravenous; LC-MS/MS: Liquid chromatography tandem mass spectrometry; MBq: Mega becquerel; MIP: Maximum intensity projections; mSv: Millisievert; NCA: Non-compartmental analysis; PET: Positron emission tomography; PET/CT: Positron emission tomography/computed tomography; PK: Pharmacokinetics; PSF: Point-spread function; ROI: Region of interest; SUV: Standard uptake values; t/p: Tissue-to-plasma; TOF: Time-of-flight; Vc: Volumes of interest; Vss: Volume of distribution at steady state

**Acknowledgements**

We wish to thank PRA Health Sciences for the management of the clinical trial.

**Funding**

This study (NCT02829307) was financially supported by GSK.

**Availability of data and materials**

Anonymised individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.

**Disclosure**

This study (NCT02829307) was financially supported by GSK. No other potential conflict of interest relevant to this article was reported. KT, AS, PG, WA, VV, MS, MBi, MC and MD are employees and shareholders of GSK. SZ, LGC, and JR were employees of GSK at the time the study was conducted. MBe was an external consultant to GSK. No conflict of interest for DV, GvD, PE, JW, and AG.

Conclusions

The study has confirmed the utility of \(^{89}\text{Zr}\)-immuno-PET as a versatile method to explore tissue distribution and organ access for proteins, demonstrating that it is possible to conduct an immuno-PET study in healthy volunteers at radiation exposure below 10 mSv. The average administered radioactivity of 14 MBq was very low but generated adequate images and reasonable quantitative information up to 7 days after administration allowing measurements of tissue penetration and elimination PK of \(^{89}\text{Zr}\)-GSK3128349.
Authors’ contributions
KT, AS, SZ, MS, MBl, MBe, and MD provided input in to the design, data acquisition, and data analysis or interpretation. LGC, PG, WA, and AG provided input in to the data acquisition and data analysis or interpretation. DV, GvD, PE, JW, JR, and MC provided input in to the design and data acquisition. WV provided input in to the design and data analysis or interpretation. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Consent for publication
All authors provided written consent for publication.

Competing interests
KT, AS, SZ, MS, MBi, and MD are employee and shareholders of GSK. KT, AS, PG, WA, VV, MS, MBi, and MD are employee and shareholders of GSK, South Collegeville Road, Collegeville, PA 19426, USA. 2GSK, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK. 3M University Medical Center, 1081 HV Amsterdam, The Netherlands. 4University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, The Netherlands.

Received: 17 January 2019 Accepted: 23 April 2019

Published online: 21 May 2019

References
1. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domain sperograms from Escherichia coli. Nature. 1989;341:544–6.
2. Jespers L, Schon O, Famm K, Winter G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol. 2004;22:1161–5.
3. Jespers L, Schon O, James LC, Veprintsev D, Winter G. Crystal structure of HEL4, a soluble, foldable human VH single domain with a germ-line scaffold. J Mol Biol. 2004;337:893–903.
4. Katz J, Bonorris G, Sellers AL. Extracellular albumin in human tissues. Clin Sci. 1970;39:725–9. https://doi.org/10.1042/cs0390725.
5. Fogh-Andersen N, Altura BM, Altura BT, Siggaard-Andersen O. Composition of interstitial fluid. Clin Chem. 1995;41:1522–5.
6. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683. https://doi.org/10.1038/nrc882.
7. Eriksson O, Espes D, SveraJak RU, Jansson E, Antoni G, Sorensen J, et al. Positron emission tomography ligand 11-hydroxy-tryptophan can be used as a surrogate marker for the human endocrine pancreas. Diabetes. 2014;63:3428–37. https://doi.org/10.2337/db13-1877.
8. Lamberts LE, Williams SP, Terwisscha van Scheltinga AG, Lube-de Hooge MN, Schroder CP, Gieterma JA, et al. Antibody positron emission tomography imaging in anticancer drug development. J Clin Oncol. 2015;33:4191–504. https://doi.org/10.1200/JCO.2014.57.8278.
9. Morgan P, Van Der Graaf PF, Anowsmith J, Feltin DE, Drummond KS, Wegner CD, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today. 2012;17:419–24. https://doi.org/10.1016/j.drudis.2011.12.020.
10. Van Dongen GA, Huisman MC, Boellaard R, Harry Hendriks N, Windhorst AD, Visser GW, et al. 89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied? Q J Nucl Med Mol Imaging. 2015;59:18–38.
11. ICRP. The 2007 recommendations of the international commission on radiological protection. ICRP publication 103. Ann ICRP. 2007;37:9–34. https://doi.org/10.1016/j.icrp.2007.10.003.
12. Vosjan M, Werd, Perk LR, Visser GWM, Budde M, Jurek P, Kiefer GE, et al. Conjugation and radiolabelling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-iodoexyacetylbenzyl-desferoximine. Nat Protoc. 2010;5:739. https://doi.org/10.1038/nprot.2010.13.
13. Verel I, Visser GWM, Boellaard R, Sgtger-van Walsum M, Snow GB, van Dongen GAMS. 89Zr Immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271–81.
14. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39:567–86. https://doi.org/10.1002/jpkp.1922.
15. Szapacs ME, Urbanski JJ, Kehler JR, Wilson R, Boram SL, Hottenstein CS, et al. Absolute quantification of a therapeutic domain antibody using ultra-performance liquid chromatography–mass spectrometry and immunoassay. Bioanalysis. 2010;2:1597–608. https://doi.org/10.1515/bio.10.70.
16. Beeken WL, Wijler W, Goldsworthy PC, Garbe LE, Reynolds WE, Stogsdill R, et al. Studies of 131-antimelanoma and distribution in normal young male adults. J Clin Invest. 1962;41:1312–33. https://doi.org/10.1172/JCI104594.
17. Tijink BM, Laeremans T, Budde M, Sgtger-van Walsum M, Dreier T, de Haard HJ, et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther. 2008;7:2288–97. https://doi.org/10.1158/1535-7163.mct-07-2384.
18. Sheridan C. Ablynx’s nanobody fragments go places antibodies cannot. Nat Biotechnol. 2013;31:1115. https://doi.org/10.1038/nbt1217-1115.
19. Sepp A, Berges A, Sanderson A, Meno-Tetang D, Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory. J Pharmacokinet Pharmacodyn. 2015;42:97–109. https://doi.org/10.1002/jpkp.2014-04302.
20. McCann FE, Pirocheau DP, Ruspi G, Blazek K, Davies ML, Feldmann M, et al. Selective TNFR1 blockade is anti-inflammatory and reveals an immunoregulatory role for TNFR2. Arthritis Rheumatol. 2014:n/a–a. https://doi.org/10.1002/art.38755.
21. Read C, Yang P, Kuc RE, Nyimanu D, Williams TL, Glen RC, et al. Apelin peptides linked to anti-serum albumin domain antibodies retain affinity in vitro and are efficacious receptor agonists in vivo. Basic Clin Pharmacol Toxicol. 2019;125:1031–7. https://doi.org/10.1111/bcpt.13227.
22. O’Connor-Semmes RL, Lin J, Hodge RJ, Andrews S, Chism J, Choudhury A, et al. GS92374697, a novel albumin binding domain antibody (AlbudAb[trade]) extends systemic exposure of exendin-4: first study in humans, PK/PD and safety. Clin Pharmacol Ther. 2014. https://doi.org/10.1038/cpt.2014.187.
23. Niederer C, Kuepfer L, Solodenko J, Eiseng T, Siegmund HJ, Block M, et al. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. J Pharmacokinet Pharmacodyn. 2018;45:235–57. https://doi.org/10.1007/s10928-017-9559-4.
24. Kamath AV. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discov Today Technol. 2016;21–22:75–83. https://doi.org/10.1016/j.dddt.2016.09.004.
25. Smith D, Minthorn E, Beerhaebe M, Pharmacokinetics and pharmacodynamics of Mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 2011;50:215–27. https://doi.org/10.2165/11531280-000000000-00000.
26. Kezer RJ, Huitema ADR, Schellens JHM, Beijnen JH, Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:493–507. https://doi.org/10.2165/11531280-000000000-00000.
27. Peters T, Albumin S. In: Bodansky O, Stewart CP, editors. Advances in clinical chemistry: Elsevier. 1970. p. 37–111. https://doi.org/10.1016/S0065-111.1970.55. https://doi.org/10.1016/j.clim.2006.09.001.
28. Kim J, Hayton WL, Robinson JM, Anderson CL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiological and therapeutic implications using a simplified mechanism-based model. Clin Immunol. 2007;122:146–55. https://doi.org/10.1016/j.clim.2006.09.001.
29. Wilg H, Gyenge C, Ivenson PO, Gullberg D, Tenstad O. The role of the extracellular matrix in tissue distribution of macromolecules in normal and pathological tissues: potential therapeutic consequences. Microcirculation. 2008;15:283–36.
30. Gyenge CC, Bowen BD, Reed RK, Bert JL. Transport of fluid and solutes in the body II. Model validation and implications. Am J Phys. 1999;277:H1228–40.
31. Gyenge CC, Bowen BD, Reed RK, Bert JL. Transport of fluid and solutes in the body I. Formulation of a mathematical model. Am J Physiol Heart Circ Physiol. 1999;277:H1215–H27.
32. Rippe B, Hanaldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev. 1994;74:163–219.
33. Perera RM, Zoncu R, Johns TG, Pypaert M, Lee F-T, Mellman I, et al. Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. Neoplasia (New York, NY). 2007;9:1099–110.
34. Mukai T, Namba S, Arano Y, Ono M, Fujisaka Y, Uehara T, et al. Synthesis and evaluation of a monoreactive DOTA derivative for indium-111-based residualizing label to estimate protein pharmacokinetics. J Pharm Pharmacol. 2002;54:1073–81. https://doi.org/10.1211/002235702320266226.
35. Birn H, Christensen El. Renal albumin absorption in physiology and pathology. Kidney Int. 2006;69:440–9.